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Abstract
Background: Despite the public health relevance of analgesic use, large-scale studies on this topic in Germany are
lacking. This study describes the prevalence, trends, associations and patterns of use of prescription and over-the-counter
(OTC) analgesics, focusing on five of the most common agents: aspirin, diclofenac, ibuprofen, naproxen and paracetamol.
Methods: Data from two representative population-based surveys: The German National Health Interview and
Examination Survey 1998 (GNHIES98 n = 7099) and the German Health Interview and Examination Survey for Adults
2008–2011 (DEGS1 n= 7091) was investigated. Information on all medicines consumed in the previous 7 days was
collected via computer-assisted personal interviews with adults aged 18–79 years. Associations between analgesic use
and socio-demographic and health-behaviour factors were analysed using logistic regression models.
Results: Analgesic use has increased over the last decade from 19 to 21 %. This was exclusively due to the rise in OTC
analgesic use from 10.0 to 12.2 %. Prescribed analgesic use remained constant (7.9 %). Findings from DEGS1 indicate that
ibuprofen is the most commonly used analgesic followed by aspirin and paracetamol. OTC analgesic use is higher among
women and smokers, but lower among older adults (65–79 years). Prescribed analgesics use is higher among women,
older adults, smokers and obese adults with medium or high socio- economic status. Adults performing more than
2 h/week of physical exercise use fewer analgesics.
Discussion: Among the adult population of Germany, the prevalence of OTC analgesic use has significantly increased
over the last decade. We found differences between adults consuming OTC and prescribed analgesics (or both)
concerning their health behaviour and health conditions. International direct comparison between prevalence rates of
analgesic use was limited due to varying availability of analgesics between countries and methodological differences.
Conclusions: About one in five community dwelling adults aged 18–79 years in Germany use analgesics in a given
week. Considering the potential harms of analgesic use, monitoring of prevalence, patterns and determinants of use at
the population level are important steps to inform disease prevention and health promotion policies.
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Background
Non-steroidal anti-inflammatory drugs (NSAIDs) and
paracetamol (acetaminophen) are essential drugs to treat
pain. The availability of medicines with analgesic effects
varies extensively between countries [1]. Debates about
the suitability of NSAIDs for over-the-counter (OTC)
sale [2] versus prescription dispensing focus on the con-
siderable health risks associated with their inappropriate
use including drug intoxication, drug interactions and
adverse drug reactions [3–6]. For example, the intake of
diclofenac, ibuprofen and naproxen increase the risk of
gastrointestinal complications by about 2–4 times and
doubles the risk of heart failure requiring hospital admis-
sion [7]. Paracetamol, a common and easily accessible
drug in many countries and included in approximately
150 preparations [8] carries risks of intoxication with 10
to 15 g reported as hepatotoxic for adults and 25 g can be
life-threatening [8]. Strong relationships between para-
cetamol sales and non-fatal overdoses in England and
France have been reported and rising sales are associated
with increasing abuse resulting in liver damage, non-fatal
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self-poisonings and suicides [9, 10]. In the US, 458 people
die per year because of paracetamol overdose and about
100 of these are accidental [11]. Since April 2009 in
Germany OTC-sales of paracetamol are restricted to 10 g
of active ingredients per package [12]. Drug regulatory
authorities and healthcare systems face challenges in
balancing the availability of analgesics in the market while
controlling their associated risks, particularly in the
context of ageing populations and rising long term
conditions.
In Germany, in addition to prescription dispensing,
aspirin, diclofenac, ibuprofen, naproxen and paracetamol
are widely available OTC at pharmacies (not supermar-
kets) and through internet pharmacies, always involving
professional pharmacists in the sale. According to the
national pharmaceutical manufacturers’ association
(‘Bundesverband der Arzneimittelhersteller e.V.’) people
in Germany spent on average just over 60€ per person on
all OTC preparations, including analgesics in 2012 [13].
Analgesic consumption is critically relevant for public
health, but representative population-based data on their
actual use is rare. Most of the existing analgesic use
studies are based on prescription-, health care insur-
ance-, or secondary care data. This study describes the
prevalence of actual analgesics use (prescribed and self-
medication) in a representative German sample of non-
institutionalized adults aged 18–79 years using data from
two German National Health Interview and Examination
Surveys (1998 and 2008–2011) conducted by the Robert
Koch Institute. We focus on five common analgesics avail-
able both OTC and with prescription in Germany [14]:
aspirin, diclofenac, ibuprofen, paracetamol and naproxen.
We describe prevalences of analgesic use, factors associ-
ated with their consumption, patterns of their use and
differences over the decade between the two surveys.
Methods
Study population
The present study is based on data from two national
health examination surveys conducted by the Robert Koch
Institute (RKI): the German National Health Interview
and Examination Survey 1998 (GNHIES98) and the
German Health Interview and Examination Survey for
Adults 2008–2011 (DEGS1) [15]. Participants were re-
cruited by a nationwide two-stage clustering sample
design in both surveys. In the first stage, communities,
representative for size, location and structure of German
communities were selected. In the second stage a rep-
resentative sample of adults aged 18–79 years was
drawn from local population registers of those communities
(7124 GNHIES98 participants from 120 communities and
8152 DEGS1 participants from 180 communities). All
GNHIES98 participants were invited to re-participate in
DEGS1 (response rate 62 %, n = 3959). An additional cross-
sectional sample of 4193 first-time participants (response
rate 42 %) was recruited for DEGS1 based on the same
sampling design, in order to achieve a nationally repre-
sentative sample of the population 18–79 years of age.
GNHIES98 and DEGS1 employ identical survey methods
and measurement protocols (self-administered question-
naires, computer-assisted personal interviews (CAPI), med-
ical examinations, physiological measurements and tests
and the collection of blood and urine samples) enabling
valid comparisons between the surveys [15, 16].
Data collection
Current medication intake was recorded via CAPI in the
local study centres. In the invitation letter, participants
were requested to bring all original packages of medi-
cines or dietary supplements they had used in the previ-
ous 7 days. Participants were asked: “Have you taken
any medicinal products or dietary supplements within
the last 7 days, such as vitamins or minerals? Please
don’t forget any painkillers, insulin preparations, medica-
tions issued by a physician, injections or plant-based
medicinal products and please also list medications from
the supermarket or drugstore”.
In the GNHIES98 study, the name of the product, the
Anatomical Therapeutic Chemical (ATC) code, the
application form (e.g. oral or topical) and the standard
package size were recorded by the interviewer manually.
In DEGS1, the information was scanned directly from
the package. Most data were collected from original
packages brought by participants. Only 1.5 % of partici-
pants needed to be subsequently contacted by telephone
or mail to complete the medicine information required.
Additionally, information on the origin of medicines
was collected. This included whether medicines were i)
prescribed by a physician; ii) prescribed by a registered
complementary medicine specialist (Heilpraktiker); iii)
were obtained OTC or from other sources (e.g. the
home medicine cabinet). Prescribed analgesic use was
defined as preparations prescribed by a physician or a
registered complementary medicine specialist. OTC an-
algesic use was defined as analgesics purchased without
prescription or non-prescribed analgesics available at
home from the medicine cabinet. Those with missing
data on the origin of analgesics were classified as “anal-
gesics from unknown origin”. If medicines were used
regularly (at least 4 days/week), duration of usage was
also recorded.
Definition and identification of analgesic use
This study focuses on five commonly used analgesics:
aspirin, diclofenac, ibuprofen, paracetamol and naproxen.
Participants were defined as “analgesic users” according to
the therapeutic effects: “analgesic”, “antipyretic” and “anti-
inflammatory” based on the ATC codes. For example,
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aspirin is indicated for multiple uses including cardiovascu-
lar disease prevention as well as an analgesic. Only ATC
codes related to analgesic effects were included and ATC
codes related to other indications were excluded. Therefore
in this analysis we restricted the included ATC codes to 7
out of 12 possible ATC codes for aspirin (A01AD05,
M01BA03, N02AA66, N02BA01, N02BA51, N02BA71 and
R05XA02); 6 out of 7 ATC codes for diclofenac (M01AB05,
M01AB55, M02AA15, N02AA65, S01BC03 and S01CC01);
5 out of 7 ATC codes for ibuprofen (D09AC04, G02CC01,
M01AE01, M01AE14 and M02AA13); and 5 out of the 7
ATC codes for paracetamol (N02AA69, N02BE01,
N02BE51, N02BE61 and R05XA01). For naproxen all 5
ATC codes (G02CC02, M01AE02, M01AE52, M01AE56
and M02AA12) were included.
Socio-demographic and health variables
Based on a literature review, we investigated a range of par-
ticipants’ characteristics for associations with analgesic use.
Socio-demographic characteristics included: age; gender;
size of municipality categorised as rural (<5000 inhabitants),
small town (5000 to <20,000 inhabitants), medium-sized
town (20,000 to <100,000 inhabitants) and city (>100,000
inhabitants); socio-economic status (SES) was measured
as an aggregated index including income, education and
occupation. Education were assessed according to the
International Standard Classification of Educational De-
grees (ISCED-97) and categorised as low, medium and
high [17, 18].
Health behaviour and conditions investigated included:
body mass index (BMI) classified as underweight
(<18.5 kg/m2), normal (18.5– <25 kg/m2), overweight
(25– <30 kg/m2) and obese: (>30 kg/m2); smoking status
categorised as regular smoker (smoking daily), occasional
smoker (smoking less than daily), ex-smoker (previously
smoking) and never-smoker; physical activity measured
using standardised questions [19] and alcohol consump-
tion measured using the Alcohol Use Disorders Identifica-
tion Test (AUDIT-C) [20]. Women and men with more
than four and five points respectively on the 12-point scale
were classified as high-risk alcohol drinkers [21].
Statistical analysis
Only participants who completed the interview on medi-
cation usage were included in the analyses (GNHIES98:
n = 7099; DEGS1: n = 7091). To examine the prevalence
of analgesic use, both cross-sectional and trend analyses
were conducted using a weighting factor which corrects
for deviations in the sample from the population struc-
ture with regard to age, sex, region of residence, and
nationality, as well as municipality size and educational
level reflecting the German population as of 31th Dec
2010 [22]. Calculation of the weighting factor also
included the re-participation probability of GNHIES98
participants, based on a logistic regression model. De-
scriptive statistics were used to examine characteristics of
the study population. Prevalence of overall analgesic use
was grouped by each of the five analgesics and by source
of origin (OTC only, prescribed only and participants
using both, OTC and prescribed analgesics). Analgesic
users were then stratified by socio-demographic and
health characteristics. Categorical variables were expressed
as percentages and 95 % confidence intervals (95 % CI)
were reported. To examine relationships between anal-
gesic use and socio-demographic characteristics and
health behaviour, unadjusted and adjusted odds ratios
(OR) and 95 % CI were determined using bivariate and
multivariable logistic regression models with analgesic use
as the dependent variable. Interactions of sex, age, SES,
BMI category, smoking and physical exercise were tested
for statistical significance. The models were run separately
for overall analgesic use, use of OTC analgesics only and
use of prescribed analgesics only. The SPSS-20 Complex
Samples method was used in the analysis to account for
the weighting and the clustering due to the two-stage
sampling procedure. Group differences were considered
statistically significant for p-values less than 0.05.
Ethical considerations
Participants provided written informed consent prior to
interview and examination in both surveys. GNHIES98
and DEGS1 were approved by the Federal and State
Commissioners for Data Protection and the Charité-
Universitätsmedizin Berlin ethics committee approved
DEGS1 as well (No. EA2/047/08).
Results
Prevalence of analgesic use
Prevalence of analgesic use in 1998 (GNHIES98) and
2008–11 (DEGS 1) are presented in Table 1. Overall,
analgesic use increased from 19.2 % in 1998 to 21.4 % in
2008–11. This is exclusively because of the significant
rise in OTC analgesic use only from 10.0 to 12.2 %.
Moreover, OTC analgesics use only increased in all sub-
groups of the population over this period, with stronger
and statistically significant increases among women,
adults aged 30–64 years, adults with low and medium
SES and adults living in rural areas. In contrast, the
prevalence of prescribed analgesic use remained con-
stant in both surveys (7.9 %); the only increase observed
over this period was among adults 30–44 years.
Prevalence and socio-demographic factors associated
with specific analgesic use in 2008–11 are presented in
Table 2. Overall, ibuprofen was the most commonly used
analgesic. Naproxen was seldom used. Women used
more ibuprofen and paracetamol than men. Paracetamol
use decreased with age while diclofenac use increased
with age. SES was associated mainly with diclofenac use;
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Table 1 Trends in prevalence of analgesic use in Germany between German Health Interview and Examination Surveys GNHIES98 and DEGS1
Study subjects Overall analgesic use OTC analgesic use only Prescription analgesic use only OTC and prescription analgesic use
GNHIES98 n = 7099 GNHIES98 DEGS1 GNHIES98 DEGS1 GNHIES98 DEGS1 GNHIES98 DEGS1
DEGS1 n = 7091 n = 1311e n = 1490e n = 696 n = 805 n = 524 n = 583 n = 36 n = 66
Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI)
Total 19.2 (18.1–20.3) 21.4 (20.1–22.6) 10.0 (9.2–10.8) 12.2 (11.2–13.2) 7.9 (7.1–8.7) 7.9 (7.1–8.7) 0.5 (0.4–0.8) 0.9 (0.6–1.2)
Gender
Men 16.1 (14.7–17.6) 17.6 (16.0–19.3) 8.2 (7.2–9.3) 9.4 (8.2–10.8) 7.0 (6.0–8.1) 7.2 (6.1–8.4) 0.3 (0.1–0.5) 0.4 (0.2–0.8)
Women 22.3 (20.7–23.9) 25.1 (23.4–27.0) 11.8 (10.6–13.1) 14.9 (13.5–16.5) 8.8 (7.7–10.0) 8.5 (7.5–9.7) 0.8 (0.5–1.3) 1.3 (0.9–1.8)
Age groups, years
18–29 17.7 (15.3–20.4) 19.5 (16.8–22.5) 13.2 (11.1–15.6) 14.8 (12.5–17.6) 2.9 (2.0–4.2) 3.2 (2.2–4.7) 0.1 (0.0–0.5) 0.7 (0.3–1.8)
30–44 19.1 (17.3–21.2) 23.8 (21.2–26.7) 13.3 (11.7–15.1) 16.4 (14.2–18.9) 4.6 (3.7–5.8) 6.8 (5.3–8.8) 0.4 (0.2–0.8) 0.3 (0.2–0.7)
45–64 19.4 (17.7–21.3) 21.6 (19.7–23.7) 9.4 (8.1–10.8) 12.0 (10.5–13.7) 8.4 (7.2–9.7) 8.3 (7.0–9.7) 1.0 (0.6–1.5) 0.8 (0.4–1.3)
65+ 20.2 (17.5–23.2) 19.5 (17.3–22.0) 3.7 (2.6–5.3) 4.5 (3.5–5.8) 15.8 (13.3–18.5) 12.8 (10.9–15.0) 0.4 (0.1–1.4) 1.9 (1.2–3.0)
Socio-economic status
Low 19.3 (16.7–22.2) 24.2 (21.3–27.4) 7.1 (5.6–9.0) 11.4 (9.3–13.9) 10.2 (8.2–12.6) 10.8 (8.9–13.2) 0.8 (0.3–1.8) 1.3 (0.7–2.6)
Medium 19.5 (18.1–21.0) 20.9 (19.4–22.5) 10.1 (9.1–11.3) 12.0 (10.8–13.3) 8.1 (7.2–9.2) 7.6 (6.7–8.7) 0.4 (0.2–0.7) 0.8 (0.5–1.2)
High 18.7 (16.5–21.1) 19.7 (17.3–22.4) 12.6 (10.7–14.6) 13.1 (11.1–15.4) 4.9 (3.8–6.4) 5.5 (4.2–7.1) 0.8 (0.4–1.5) 0.7 (0.4–1.2)
Municipality size
Rurala 16.3 (14.4–18.5) 20.1 (17.5–23.1) 7.8 (6.4–9.4) 10.9 (8.9–13.2) 7.8 (6.4–9.5) 8.0 (6.3–10.2) 0.4 (0.2–1.0) 0.8 (0.4–1.7)
Small townb 16.8 (14.7–19.1) 19.5 (17.3–21.9) 7.7 (6.4–9.3) 9.9 (8.3–11.7) 7.4 (6.0–9.2) 8.3 (6.8–10.1) 0.3 (0.1–0.9) 1.0 (0.5–1.9)
Townc 20.3 (18.3–22.6) 22.0 (19.9–24.3) 10.9 (9.3–12.6) 13.2 (11.4–15.2) 8.3 (6.9–10.0) 7.2 (5.9–8.6) 0.5 (0.2–0.9) 1.2 (0.7–1.9)
Cityd 21.4 (19.4–23.6) 22.8 (20.5–25.4) 12.0 (10.4–13.7) 13.6 (11.7–15.8) 7.8 (6.5–9.4) 8.1 (6.7–9.8) 0.8 (0.5–1.5) 0.5 (0.3–0.9)
Bold text denotes statistical significance (p < 0.05) when comparing GNHIES98 with DEGS1
a = <5000 inhabitants. b = 5000 to <20,000 inhabitants. c = 20,000 to <100,000 inhabitants. d = ≥100,000 inhabitants














those with lower SES were more likely to use diclofenac
and naproxen than other SES groups.
In 2008–11, women’s use of analgesics was signifi-
cantly higher than men’s (25.1 % vs. 17.6 %, OR = 1.58,
95 % CI 1.35–1.85). Figure 1 presents the prevalence of
analgesic use in the last 7 days by age and gender. Analgesic
consumption was lowest among men aged 18–29 years and
highest among women aged 30–44 years.
Regardless of the source of origin (OTC or prescribed),
11.0 % (164/1490) of analgesic users consumed two
different analgesics (of the five pharmaceutical active in-
gredients examined) during the 7 day period. Among
these, 4.9 % (74/1490) used a combination of paracetamol
with an NSAID, most frequently ibuprofen. 6.0 % of the
participants (90/1490) report using two different NSAIDs
during the 7-day period; these were predominately combi-
nations of diclofenac and aspirin or ibuprofen. Only 0.9 %
(66/1490) of analgesic users reported using both OTC and
prescribed analgesics during the 7 days.
In 2008–11, 4.5 % of the population consumed anal-
gesics regularly (at least 4 days/week). Of these, most re-
ported using prescribed analgesics regularly (3.7 %; 95 %
CI 3.2–4.3) and fewer reported regular OTC analgesic
use (0.8 %; 95 % CI 0.6–1.1). Regarding the duration of
use, 0.6 % of the population used OTC analgesics regu-
larly and for more than 7 days and for prescribed analge-
sics the prevalence was higher (3.2 %).
Associations of analgesic use with socio-demographic and
health characteristics
Table 3 presents the bivariate logistic regression analyses
and the associations between analgesics use and socio-
demographic and health characteristics. Overall analgesic
use was higher among women; adults aged 30–44 years,
adults with obesity and smokers. Participants with high
education levels and those performing more than 4 h of
Table 2 Prevalence of specific analgesic use among the adult population in Germany. German Health Interview and Examination
Survey for Adults (DEGS1) 2008–2011
Analgesic use Aspirin n = 399 Diclofenac n = 352 Ibuprofen n = 352 Paracetamol n = 330 Naproxen n = 12
Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI) Prevalence (95 % CI)
Total 5.8 (5.1–6.6) 4.4 (3.8–5.0) 8.0 (7.2–8.9) 5.2 (4.6–5.9) 0.2 (0.1–0.3)
Gender
Men* 5.2 (4.3–6.2) 4.3 (3.5–5.2) 5.7 (4.8–6.8) 4.0 (3.2–4.9) 0.1 (0.0–0.4)
Women 6.3 (5.3–7.5) 4.4 (3.7–5.3) 10.3 (9.1–11.6) 6.4 (5.4–7.6) 0.2 (0.1–0.4)
Age groups, years
18–29* 4.8 (3.3–6.9) 1.2 (0.6–2.2) 8.8 (7.0–11.0) 6.9 (5.3–9.1) 0.0 (0.0–0.0)
30–44 5.7 (4.2–7.6) 2.8 (1.9–4.3) 9.5 (7.8–11.4) 7.0 (5.6–8.7) 0.2 (0.1–0.7)
45–64 6.5 (5.3–7.8) 4.7 (3.9–5.7) 7.7 (6.4–9.1) 4.5 (3.5–5.7) 0.1 (0.0–0.3)
65+ 5.4 (4.3–6.9) 8.8 (7.1–10.7) 6.0 (4.7–7.7) 2.6 (1.7–4.1) 0.4 (0.1–1.3)
Socio-economic status
Low* 4.8 (3.3–6.8) 6.5 (5.0–8.5) 9.5 (7.5–12.1) 5.2 (3.6–7.3) 0.4 (0.2–1.1)
Medium 5.6 (4.7–6.7) 3.9 (3.3–4.7) 7.9 (7.0–9.0) 5.5 (4.6–6.5) 0.1 (0.0–0.3)
High 7.1 (5.8–8.7) 3.6 (2.6–4.9) 6.8 (5.3–8.6) 4.1 (3.0–5.7) 0.0 (0.0–0.3)
Municipality size
Rurala* 5.1 (3.7–7.0) 5.8 (4.2–8.0) 7.1 (5.4–9.3) 3.8 (2.9–5.0) 0.1 (0.0–0.7)
Small townb 5.0 (4.0–6.3) 3.9 (2.9–5.3) 7.0 (5.7–8.6) 5.1 (4.0–6.6) 0.2 (0.1–0.6)
Townc 5.9 (4.8–7.2) 4.6 (3.7–5.8) 8.6 (7.3–10.2) 5.6 (4.5–7.0) 0.1 (0.0–0.4)
Cityd 6.6 (5.1–8.4) 3.7 (2.8–4.8) 8.7 (7.2–10.3) 5.6 (4.3–7.2) 0.2 (0.1–0.8)
Bold text denotes statistical significance (p < 0.05) in comparison with the reference (*)









18-29 years 30-44 years 45-64 years 65+ years
Men
Women
Fig. 1 Prevalence of analgesic use among the adult population in
Germany by age and gender; German Health Interview and Examination
Survey for Adults (DEGS1) 2008–2011
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Table 3 Bivariate logistic regression analysis: prevalence and factors associated with analgesic use among the adult population in Germany. German Health Interview and
Examination Survey for Adults (DEGS1) 2008–2011
Study Overall analgesic use n = 1490b OTC analgesic use only n = 805 Prescription analgesic use only n = 583 OTC and prescription analgesic use n = 66
Subjects Prevalence Unadjusted Prevalence Unadjusted Prevalence Unadjusted Prevalence Unadjusted
n (%) (95 % CI) OR (95 % CI) (95 % CI) OR (95 % CI) (95 % CI) OR (95 % CI) (95 % CI) OR (95 % CI)
Total 7091 (100) 21.4 (20.1–22.6) - 12.2 (11.2–13.2) - 7.9 (7.1–8.7) - 0.9 (0.6–1.2) -
Gender
Mena 3399 (49.7) 17.6 (16.0–19.3) 1.00 9.4 (8.2–10.8) 1.00 7.2 (6.1–8.4) 1.00 0.4 (0.2–0.8) 1.00
Women 3692 (50.3) 25.1 (23.4–27.0) 1.58 (1.35–1.85) 14.9 (13.5–16.5) 1.68 (1.36–2.07) 8.5 (7.5–9.7) 1.21 (0.97–1.49) 1.3 (0.9–1.8) 2.87 (1.39–5.94)
Age groups, years
18–29a 1065 (18.8) 19.5 (16.8–22.5) 1.00 14.8 (12.5–17.6) 1.00 3.2 (2.2–4.7) 1.00 0.7 (0.3–1.8) 1.00
30–44 1426 (25.1) 23.8 (21.2–26.7) 1.29 (1.01–1.66) 16.4 (14.2–18.9) 1.13 (0.85–1.49) 6.8 (5.3–8.8) 2.19 (1.33–3.61) 0.3 (0.2–0.7) 0.49 (0.14–1.76)
45–64 2750 (36.5) 21.6 (19.7–23.7) 1.14 (0.93–1.39) 12.0 (10.5–13.7) 0.78 (0.62–0.98) 8.3 (7.0–9.7) 2.68 (1.74–4.13) 0.8 (0.4–1.3) 1.11 (0.38–3.31)
65+ 1850 (19.6) 19.5 (17.3–22.0) 0.99 (0.79–1.26) 4.5 (3.5–5.8) 0.27 (0.19–0.37) 12.8 (10.9–15.0) 4.38 (2.78–6.89) 1.9 (1.2–3.0) 2.79 (0.92–8.52)
Socio-economic status
Lowa 1156 (19.7) 24.2 (21.3–27.4) 1.00 11.4 (9.3–13.9) 1.00 10.8 (8.9–13.2) 1.00 1.3 (0.7–2.6) 1.00
Medium 4206 (60.1) 20.9 (19.4–22.5) 0.83 (0.67–1.02) 12.0 (10.8–13.3) 1.07 (0.81–1.40) 7.6 (6.7–8.7) 0.68 (0.52–0.89) 0.8 (0.5–1.2) 0.58 (0.27–1.26)
High 1685 (20.2) 19.7 (17.3–22.4) 0.77 (0.61–0.98) 13.1 (11.1–15.4) 1.17 (0.87–1.58) 5.5 (4.2–7.1) 0.48 (0.33–0.68) 0.7 (0.4–1.2) 0.52 (0.21–1.32)
Education status (ISCED)
Low 1003 (21.1) 20.3 (17.6–23.3) 0.87 (0.71–1.05) 10.6 (8.5–13.2) 0.80 (0.61–1.05) 8.2 (6.7–10.1) 0.97 (0.74–1.28) 1.2 (0.6–2.2) 1.39 (0.63–3.04)
Mediuma 3773 (55.1) 22.8 (21.2–24.4) 1.00 12.9 (11.6–14.3) 1.00 8.4 (7.4–9.6) 1.00 0.9 (0.6–1.3) 1.00
High 2271 (23.7) 18.7 (16.6–20.9) 0.78 (0.66–0.92) 11.6 (9.8–13.8) 0.89 (0.70–1.13) 6.0 (4.9–7.4) 0.69 (0.54–0.91) 0.6 (0.4–1.0) 0.69 (0.37–1.32)
Body Mass Index (BMI)
Underweight (<18.5) 93 (1.5) 26.5 (16.6–39.5) 1.77 (0.79–2.64) 22.1 (13.0–35.2) 1.79 (0.93–3.44) 4.4 (0.9–18.1) 0.80 (0.16–3.95) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Normal (18.5–< 25)a 2599 (38.4) 20.0 (18.3–21.9) 1.00 13.7 (12.3–15.3) 1.00 5.4 (4.4–6.6) 1.00 0.3 (0.2–0.7) 1.00
Overweight (25–< 30) 2651 (36.4) 20.5 (18.4–22.7) 1.03 (0.86–1.23) 11.2 (9.6–13.1) 0.79 (0.64–0.99) 8.2 (6.9–9.7) 1.57 (1.17–2.09) 0.8 (0.5–1.2) 2.57 (1.08–6.14)
Obese (≥30) 1698 (23.6) 24.7 (22.1–27.5) 1.31 (1.09–1.57) 10.7 (9.0–12.6) 0.75 (0.61–0.93) 11.6 (9.9–13.7) 2.31 (1.75–3.06) 1.9 (1.2–3.0) 5.97 (2.52–14.2)
Smoking status
Never-smokera 3067 (42.0) 19.1 (17.5–20.9) 1.00 10.8 (9.4–12.3) 1.00 7.0 (5.9–8.2) 1.00 0.9 (0.5–1.4) 1.00
Ex-smoker 2111 (28.1) 20.2 (17.9–22.7) 1.07 (0.88–1.29) 10.1 (8.5–12.0) 1.65 (1.32–2.07) 8.3 (6.8–10.2) 1.21 (0.89–1.63) 1.2 (0.7–2.0) 0.67 (0.23–1.95)
Occasional-smoker 415 (6.1) 20.7 (16.4–25.8) 1.10 (0.81–1.50) 13.7 (10.1–18.3) 1.31 (0.89–1.92) 6.5 (4.0–10.5) 0.93 (0.53–1.61) 0.5 (0.2–1.6) 0.59 (0.17–2.08)














Table 3 Bivariate logistic regression analysis: prevalence and factors associated with analgesic use among the adult population in Germany. German Health Interview and
Examination Survey for Adults (DEGS1) 2008–2011 (Continued)
Physical exercise hours/week (h/w)
None 2210 (33.1) 22.5 (20.5–24.6) 1.00 (0.85–1.18) 12.1 (10.3–14.1) 0.94 (0.74–1.19) 9.0 (7.7–10.5) 1.08 (0.86–1.37) 0.9 (0.6–1.4) 1.06 (0.55–2.02)
Up to 2 h/wa 2952 (41.4) 22.5 (20.6–24.4) 1.00 12.8 (11.2–14.5) 1.00 8.4 (7.2–9.7) 1.00 0.9 (0.6–1.4) 1.00
2–4 h/w 1078 (15.2) 19.0 (16.4–21.9) 0.81 (0.65–1.00) 13.3 (11.2–15.6) 1.04 (0.82–1.34) 4.7 (3.2–6.9) 0.54 (0.36–0.83) 0.3 (0.1–0.8) 0.35 (0.12–0.99)
More than 4 h/w 657 (10.3) 17.2 (13.9–21–2) 0.72 (0.54–0.95) 11.0 (8.3–14.5) 0.84 (0.59–1.19) 5.1 (3.5–7.5) 0.59 (0.38–0.92) 0.8 (0.2–2.8) 0.85 (0.21–3.45)
High risk alcohol drinking
Noa 4571 (66.6) 21.3 (20.0–22.8) 1.00 11.8 (10.7–13.0) 1.00 8.3 (7.4–9.3) 1.00 0.7 (0.5–1.1) 1.00
Yes 2252 (33.4) 21.7 (19.5–24.1) 1.02 (0.87–1.19) 13.7 (11.9–15.8) 1.19 (0.98–1.44) 6.7 (5.4–8.3) 0.79 (0.62–1.03) 0.9 (0.5–1.6) 1.23 (0.63–2.42)
Odds ratio (OR) and its 95 % confidence intervals (95 % CI) are obtained from bivariate analysis. Bold text denotes statistical significance (p < 0.05) in comparison with the reference
aReference group. All percentages are weighted according to the adult German population














physical exercise per week consumed significantly less
analgesics. Among all analgesic users (n = 1490), more
participants reported consuming only OTC analgesics
compared to only prescribed analgesics (12.2 % vs. 7.9 %).
OTC use was higher among women and smokers, but
lower among those aged 45 years and older and among
overweight or obesity adults.
Among participants reporting only taking prescribed anal-
gesics, we found a strong association between increased age
and the use of prescribed analgesics (Table 3). Adults with
low SES use significantly more prescribed analgesics than
adults with high SES. Higher education status is associated
with less prescribed analgesic use. Being overweight or obese
is associated with higher levels of prescribed analgesics. Per-
forming 2 or more hours of physical activity per week was
associated with lower prescribed analgesic use (Table 3).
Among all analgesic users (n = 1490), a total of 66
adults reported using both OTC and prescribed analge-
sics during the 7 days prior to the medical interview,
demonstrating a weighted prevalence of 0.9 % (95 % CI
0.6–1.2 %). Significantly more women use both, OTC
and prescribed analgesics in comparison to men.
Table 4 presents the multivariable logistic regression
analysis. This analysis included socio-demographic
Table 4 Multivariable logistic regression analysis: prevalence and factors associated with analgesic use, exclusively using OTC analgesics
and exclusively using prescribed analgesics among the adult population in Germany German Health Interview and Examination Survey
for Adults (DEGS1) 2008–2011
Study Analgesic use n = 1490b OTC analgesic use only n = 805 Prescribed analgesic use only n = 583
Subjects Prevalence Adjusted Prevalence Adjusted Prevalence Adjusted
n (%) (95 % CI) OR (95 % CI) (95 % CI) OR (95 % CI) (95 % CI) OR (95 % CI)
Total 7091 (100) 21.4 (20.1–22.6) - 12.2 (11.2–13.2) - 7.9 (7.1–8.7) -
Gender
Mena 3399 (49.7) 17.6 (16.0–19.3) 1.00 9.4 (8.2–10.8) 1.00 7.2 (6.1–8.4) 1.00
Women 3692 (50.3) 25.1 (23.4–27.0) 1.63 (1.38–1.92) 14.9 (13.5–16.5) 1.71 (1.37–2.14) 8.5 (7.5–9.7) 1.28 (1.02–1.62)
Age groups, years
18–29a 1065 (18.8) 19.5 (16.8–22.5) 1.00 14.8 (12.5–17.6) 1.00 3.2 (2.2–4.7) 1.00
30–44 1426 (25.1) 23.8 (21.2–26.7) 1.27 (0.98–1.64) 16.4 (14.2–18.9) 1.16 (0.87–1.54) 6.8 (5.3–8.8) 1.98 (1.19–3.28)
45–64 2750 (36.5) 21.6 (19.7–23.7) 1.05 (0.84–1.33) 12.0 (10.5–13.7) 0.80 (0.61–1.05) 8.3 (7.0–9.7) 2.19 (1.41–3.43)
65+ 1850 (19.6) 19.5 (17.3–22.0) 0.95 (0.73–1.23) 4.5 (3.5–5.8) 0.31 (0.22–0.44) 12.8 (10.9–15.0) 3.64 (2.28–5.82)
Socio-economic status
Lowa 1156 (19.7) 24.2 (21.3–27.4) 1.00 11.4 (9.3–13.9) 1.00 10.8 (8.9–13.2) 1.00
Medium 4206 (60.1) 20.9 (19.4–22.5) 0.85 (0.68–1.07) 12.0 (10.8–13.3) 1.03 (0.77–1.38) 7.6 (6.7–8.7) 0.72 (0.54–0.95)
High 1685 (20.2) 19.7 (17.3–22.4) 0.87 (0.66–1.15) 13.1 (11.1–15.4) 1.13 (0.81–1.58) 5.5 (4.2–7.1) 0.62 (0.41–0.92)
Body Mass Index (BMI)
Normal (18.5–< 25)a 2599 (38.4) 20.0 (18.3–21.9) 1.00 13.7 (12.3–15.3) 1.00 5.4 (4.4–6.6) 1.00
Overweight (25–< 30) 2651 (36.4) 20.5 (18.5–22.8) 1.08 (0.90–1.30) 11.2 (9.6–13.1) 0.97 (0.77–1.23) 8.2 (6.9–9.7) 1.27 (0.94–1.71)
Obese (≥30) 1698 (23.6) 24.8 (22.2–27.6) 1.33 (1.09–1.62) 10.7 (9.0–12.6) 1.02 (0.81–1.29) 11.6 (9.9–13.7) 1.60 (1.18–2.19)
Smoking status
Never-smokera 3067 (42.0) 19.1 (17.5–20.9) 1.00 10.8 (9.4–12.3) 1.00 7.0 (5.9–8.2) 1.00
Ex-smoker 2111 (28.1) 20.2 (17.9–22.7) 1.16 (0.95–1.41) 10.1 (8.5–12.0) 1.09 (0.84–1.41) 8.3 (6.8–10.2) 1.17 (0.85–1.62)
Occasional smoker 415 (6.1) 20.7 (16.4–25.8) 1.16 (0.85–1.57) 13.7 (10.1–18.3) 1.20 (0.82–1.75) 6.5 (4.0–10.5) 1.16 (0.72–1.89)
Smoker 1460 (23.7) 26.6 (23.9–29.5) 1.55 (1.28–1.88) 16.6 (14.4–19.0) 1.55 (1.22–1.95) 9.0 (7.3–10.9) 1.53 (1.10–2.13)
Physical exercise hours/week (h/w)
Nonea 2210 (33.1) 22.5 (20.5–24.6) 1.00 12.1 (10.3–14.1) 1.00 9.0 (7.7–10.5) 1.00
Up to 2 h/w 2952 (41.4) 22.5 (20.6–24.5) 1.08 (0.91–1.27) 12.8 (11.2–14.5) 1.08 (0.86–1.36) 8.4 (7.2–9.7) 1.08 (0.85–1.38)
More than 2 h/w 1735 18.3 (16.2–20.7) 0.91 (0.74–1.13) 12.3 (10.5–14.4) 1.08 (0.81–1.42) 4.9 (3.8–6.3) 0.71 (0.51–0.99)
Odds ratio (OR) and its 95 % confidence intervals (95 % CI) are obtained from multivariable logistic regression models with analgesic use, only OTC analgesic use
or only prescribed analgesic use, respectively as dependent variable and all other variables shown in the table as independent variables. Bold text denotes
statistical significance (p < 0.05) in comparison with the reference
aReference group. All percentages are weighted according to the adult German population
bAnalgesics of unknown origin (n = 36)
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variables (sex, age and SES) and health behavioral factors
that can influence the use of analgesic such as physical
exercise, smoking and BMI. Women were more likely to
consume analgesics (OR = 1.63, 95 % CI 1.38–1.92) as were
those currently smoking (OR = 1.55, 95 % CI 1.28–1.88)
and those with obesity (OR = 1.33, 95 % CI 1.09–1.62).
Adults 65 years and older were more likely to use only pre-
scribed analgesics (OR = 3.64, 95 % CI 2.28–5.82) and less
likely to use OTC analgesics (OR = 0.31, 95 % CI
0.22–0.44) compared to all other age groups. Adults
with medium or high SES were less likely to use only
prescribed analgesics. Obese adults were more likely to
consume only prescribed analgesics (OR = 1.60, 95 % CI
1.18–2.19). Adults performing physical exercise for more
than 2 h a week were less likely to consume only
prescribed analgesics (OR = 0.71, 95 % CI 0.51–0.99)
compared to adults performing no physical exercise.
Table 5 presents the multivariable analysis including
tests for interaction. Significant interaction terms were
only found when prescription analgesic use only was the
dependent variable (Table 5). There was a significant
interaction between SES and BMI, where the association
between obesity and a more frequent use of prescribed
analgesics was not present among participants with a
low SES. Likewise, the association between higher SES
and a lower rate of prescribed analgesics use only was
not present among obese adults. Results regarding the
other factors were unaltered compared to Table 4.
Regarding factors associated with regular analgesic
use, we did not find any socio-demographic nor health
related factor associated with the regular OTC-analgesic
use. However, factors positively associated with the regu-
lar prescribed analgesic use were: being male, older age,
low SES, obesity and smoking.
Discussion
Among the adult population of Germany, the prevalence
of analgesic use has increased over the last decade. This
rise is exclusively due to an increased in the OTC anal-
gesic use, which was most notable among women and
those with low SES. Furthermore, there are differences
between adults consuming OTC and prescribed analge-
sics (or both) concerning their health behaviour and
health conditions.
In Germany about one fifth of adults use analgesics in
a given week; 12 % use exclusively OTC analgesics and
8 % use prescription analgesics exclusively. International
direct comparison between prevalence rates of analgesic
use is limited due to varying availability of analgesics
between countries and to methodological differences, in
particular, in the period of analgesic use investigated
between studies. Nevertheless, our findings are compar-
able to the Slone Survey, a US telephone survey investi-
gating medicines and supplements use in the previous
7 days, reporting that prescription and OTC analgesics
are the most frequently used medical products among
adults and are consumed by 17 to 23 % of the population
[23]. Similarly, a contemporary study in France using na-
tional health insurance claims data investigating the usage
patterns of OTC versus prescription NSAIDs (ibuprofen,
diclofenac, naproxen and ketoprofen) reported that about
20 % of people receive at least one reimbursement of an
OTC or prescription NSAID per year [24]. Similarly, an
investigation of the patterns of NSAIDs use, based on
population-level survey data from Denmark between 1997
and 2005, found that 15–17 % of people receive at least
one prescription of NSAIDs (ibuprofen, diclofenac, na-
proxen, rofecoxib, celecoxib) per year [25]. However, pre-
scription data from health insurance system cannot reflect
the actual use of analgesics in the population as packages
could be taken only partly and not all studies include
private prescriptions and OTC self-medication. Further-
more, with prescription data it is not possible to estimate
OTC use. Our survey data and the robust data collection
methods we used to collect details about medicines taken
in the previous 7 days may be more likely to reflect actual
medicines consumed and not just prescribed.
In our study, OTC analgesic use significantly increased
from 10 to 12 % within a decade. There are contextual
trends that may explain this rise, e.g. as more analgesics
move from prescription to OTC status, possibly leading
to an increase of OTC analgesic use [26]. Availability,
convenience, costs and product marketing are likely to
impact on OTC analgesics use and self-medication in
general. For example, an individual may consider the
availability of local pharmacies, the convenience of at-
tending their physician and costs associated with travel.
Purchasing costs, including free of charge prescription
medication may differ for individuals and are interre-
lated with personal circumstances and health insurance
coverage. Rises in OTC analgesic use may be related to
rising painful musculoskeletal chronic conditions, such
as arthritis [27].
We found that the most commonly used analgesic in
Germany is ibuprofen, followed by aspirin, paracetamol,
diclofenac and naproxen. Higher frequency of use of
ibuprofen compared to diclofenac has been reported in
numerous countries including Denmark [28], the US
[29] and in a comparative study of analgesic consumption
in Slovakia, Norway and Finland [30]. An Australian study
investigating patterns of OTC analgesic use between 2001
and 2009 finds a 15 % increase in the use of ibuprofen,
naproxen, and diclofenac, whereas the relative use of para-
cetamol and aspirin declines by 14 and 4 % respectively,
but an overall rise in the use of OTC NSAIDs is observed
[31]. Conversely, there is evidence that OTC and pre-
scribed diclofenac is more frequently used than ibuprofen
in Serbia [32]. Furthermore, the afore cited Serbian study
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investigates trends over time for 2 years (2004–2006) and
reports that, although there is an overall decline in the use
of prescribed and OTC NSAIDs, OTC diclofenac and
ibuprofen use increases over this period [32].
Naproxen is used comparatively rarely in Germany des-
pite evidence that naproxen is associated with less vascu-
lar risk than other NSAIDs including ibuprofen and
diclofenac [7]. Guidelines recommend the use of naproxen
as the NSAID of choice for those at risk of cardiovascular
complications [33, 34]. Low rates of naproxen use and
prescribers and individuals preferences for certain
NSAIDs and analgesics are influenced by a variety of
factors, including the timing of introduction of an NSAID
to the market [33] and pricing. Similar to other studies
[2, 31], we find that 6 % (90/1490) of analgesic users
consumed two different types of NSAIDs within the
previous week. Using certain types of NSAID analgesics
simultaneously at certain dosages and within specified
time periods is contra-indicated and bears a high risk of
adverse health events, such as gastric bleeding [35, 36]
and myocardial infarction (MI) [37]. In our study, the
proportion of adults, who uses regularly and for more
than 7 days analgesics is relatively low (0.6 %). However,
regular and long-term use of analgesics is linked to health
risks [38] and further studies investigating those taking
long term analgesics are required to understand the
reasons for their use.
People aged 65 years or older as well as those with low
SES use more diclofenac compared to other age groups.
The vascular risks of high-dose diclofenac [7], particularly
the risk of MI and death [25] are well established. Safety
advice issued for diclofenac by the European Safety
Agency, outlines how the drug is contra-indicated for
people with established chronic heart failure, ischaemic
heart disease, peripheral artery disease or cerebrovascular
disease [39]. Older aged adults and people with low SES
are more likely to suffer from cardiovascular disease [40],
and our findings of increased diclofenac use among these
groups warrants further investigation and explanation.
Table 5 Multivariable logistic regression and interaction
analysis: prevalence and factors associated with prescribed
analgesic use among the adult population in Germany. German
Health Interview and Examination Survey for Adults (DEGS1)b
2008–2011
Prescribed analgesic use only
n = 583
Prevalence Adjusted
(95 % CI) OR (95 % CI)
Total 7.9 (7.1–8.7) -
Gender
Mena 7.2 (6.1–8.4) 1.00
Women 8.5 (7.5–9.7) 1.30 (1.04–1.64)
Age groups, years
18–29a 3.2 (2.2–4.7) 1.00
30–44 6.8 (5.3–8.8) 2.04 (1.22–3.40)
45–64 8.3 (7.0–9.7) 2.21 (1.42–3.47)
65+ 12.8 (10.9–15.0) 3.67 (2.29–5.87)
Smoking status
Never smokera 7.0 (5.9–8.2) 1.00
Ex-smoker 8.3 (6.8–10.2) 1.17 (0.84–1.62)
Occasional smoker 6.5 (4.0–10.5) 1.20 (0.73–1.95)
Smoker 9.0 (7.3–10.9) 1.52 (1.09–2.11)
Physical exercise hours/week (h/w)
Nonea 9.0 (7.7–10.5) 1.00
Up to 2 h/w 8.4 (7.2–9.7) 1.08 (0.85–1.38)
More than 2 h/w 4.9 (3.8–6.3) 0.72 (0.52–0.99)
Body Mass Index (BMI) by
socio-economic status
Low SES: Normal 7.6 (5.1–11.1) 0.87 (0.45–1.67)
Low SES: Overweight 14.0 (10.1–19.1) 1.44 (0.81–2.56)
Low SES: Obesea 11.0 (7.6–15.8) 1.00
Medium SES: Normal 5.6 (4.3–7.2) 0.64 (0.44–0.92)
Medium SES: Overweight 7.7 (6.1–9.6) 0.71 (0.50–1.02)
Medium SES: Obesea 11.1 (8.8–13.8) 1.00
High SES: Normal 3.6 (2.2–6.0) 0.28 (0.14–0.56)
High SES: Overweight 5.2 (3.5–7.7) 0.37 (0.18–0.75)
High SES: Obesea 13.9 (8.7–21.5) 1.00
Socio-economic status by Body
Mass Index (BMI)
Normal: Low SES 7.6 (5.1–11.1) 2.07 (1.03–4.16)
Normal: Medium SES 5.6 (4.3–7.2) 1.52 (0.82–2.83)
Normal: High SESa 3.6 (2.2–6.0) 1.00
Overweight: Low SES 14.0 (10.1–19.1) 2.60 (1.42–4.78)
Overweight: Medium SES 7.7 (6.1–9.6) 1.29 (0.79–2.12)
Overweight: High SESa 5.2 (3.5–7.7) 1.00
Table 5 Multivariable logistic regression and interaction
analysis: prevalence and factors associated with prescribed
analgesic use among the adult population in Germany. German
Health Interview and Examination Survey for Adults (DEGS1)b
2008–2011 (Continued)
Obese: Low SES 11.0 (7.6–15.8) 0.67 (0.33–1.34)
Obese: Medium SES 11.1 (8.8–13.8) 0.67 (0.37–1.21)
Obese: High SESa 13.9 (8.7–21.5) 1.00
Odds ratio (OR) and its 95 % confidence intervals (95 % CI) are obtained from
multivariable logistic regression models with exclusively prescribed analgesic
use, as dependent variable and all other variables shown in the table as
independent variables. Bold text denotes statistical significance (p < 0.05) in
comparison with the reference
aReference group. All percentages are weighted according to the adult
German population
bAnalgesics of unknown origin (n = 36)
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We found in our study that the rise in analgesic use
over the past decade occurred mainly among those aged
30–44 years consistent with others reporting that youn-
ger people use more OTC analgesics than older people
and that older people use more prescribed analgesics
than younger people [31, 41]. We found women consume
more analgesics than men, particularly more ibuprofen
and paracetamol, consistent with others [31, 41–44].
There is evidence of a social gradient in analgesic use in
Germany, in line with other studies conducted in Euro-
pean countries [2, 45]. People with low SES take more
prescribed analgesics compared to those with high SES
and high educational levels.
In our study certain health-behaviour factors were
related to analgesics use. Similar to other studies, smok-
ing was associated with a high prevalence of analgesic
use [41, 46, 47]. This could be due to the fact that smok-
ing is strongly associated with having more pain [48, 49].
We also observed a significant association between obes-
ity and consuming more prescribed analgesics. Toblin et
al. [50] have found that obesity was a risk factor for pain.
Furthermore, in a Swedish study, being overweight was as-
sociated with more prescribed analgesic use among men
and with more OTC analgesic use among women [41]. The
association between obesity with activity difficulty because
of pain was previously studied [51]. In our study, adults
performing physical exercise for more than 4 h per week
used fewer analgesics. Another study reported associations
between higher exercise activities and more OTC con-
sumption compared to prescribed analgesic use [52].
One of the main strengths of our study is the large
nationally representative sample of non-institutionalised
adults in Germany [22]. However, we recognise that
response rates among newly recruited study participants in
DEGS1 are lower than response rates of former GNHIES98
participants (42 % versus 62 %) [15]. We attempted to
minimise response bias by applying corrective weights in
our analysis. In both national surveys, GNHIES98 and
DEGS1, people with severe diseases and impairments are
likely to be under-represented and this analysis had an
upper age limit of inclusion of 79 years. This could possibly
have resulted in an underestimation of analgesic use.
In GNHIES98 and DEGS1 information on drug use was
collected directly from participants and both, prescribed
and OTC analgesic use was recorded. Collecting self-
reported information on the use of medicines has strengths
and limitations. Robust data collection methods using
standardised CAPIs and scanning of original medicines
packaging at the study centre improves the validation of
self-reported medicines use [53]. By scanning the central
pharmaceutical number, all information on the preparation,
such as the name and ATC code, are transferred automatic-
ally to the database reducing the likelihood of transcription
error. Restricting data collection in the survey to drug use
during the last 7-days attempts to minimise errors due to
poor memory, however the possibility of recall bias cannot
be excluded. Furthermore, medicines used cyclically within
and out of this 7-day time period could lead to misclassifi-
cation and may potentially overestimate or underestimate
the use of certain medicines.
Conclusions
Based on nationally representative data the present study
found that about one in five adults in Germany utilizes
analgesics in a typical week. Rising use of analgesics over
time is predominantly explained by increasing analgesics
use among those aged 30–44 years and by rising OTC
analgesic use, particularly among women and those with
low SES. Levels of prescribed analgesic use in Germany
remain the same as a decade ago. Ibuprofen is the most
commonly used analgesic and women use more ibupro-
fen and paracetamol than men. Significant relationships
exist between analgesics use and factors including age,
gender, SES and health behaviour. Considering the po-
tential harms of prolonged analgesic use, patterns of use
at the population level need to be monitored in more
detail. Further studies on high risk groups, those with
co-morbidities, and those consuming multiple medicines
are needed. Furthermore, patterns of analgesic use need
to be examined in the context of pain management prac-
tice. Health policy planners and health workers face
challenges with rising analgesics use and closer monitor-
ing of adverse events and ways to minimise their risks
are needed.
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